Cargando…

Safinamide in Clinical Practice: A Spanish Multicenter Cohort Study

Background: Safinamide is an approved drug for the treatment of motor fluctuations of Parkinson’s Disease (PD) patients with a potential benefit on non-motor symptoms (NMS). Methods: A retrospective multicenter cohort study was conducted, in which the clinical effect of safinamide on both motor and...

Descripción completa

Detalles Bibliográficos
Autores principales: Martí-Andrés, Gloria, Jiménez-Bolaños, Rayco, Arbelo-González, José Matias, Pagonabarraga, Javier, Duran-Herrera, Carmen, Valenti-Azcarate, Rafael, Luquin, Mª Rosario
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6826846/
https://www.ncbi.nlm.nih.gov/pubmed/31614574
http://dx.doi.org/10.3390/brainsci9100272
_version_ 1783465187877060608
author Martí-Andrés, Gloria
Jiménez-Bolaños, Rayco
Arbelo-González, José Matias
Pagonabarraga, Javier
Duran-Herrera, Carmen
Valenti-Azcarate, Rafael
Luquin, Mª Rosario
author_facet Martí-Andrés, Gloria
Jiménez-Bolaños, Rayco
Arbelo-González, José Matias
Pagonabarraga, Javier
Duran-Herrera, Carmen
Valenti-Azcarate, Rafael
Luquin, Mª Rosario
author_sort Martí-Andrés, Gloria
collection PubMed
description Background: Safinamide is an approved drug for the treatment of motor fluctuations of Parkinson’s Disease (PD) patients with a potential benefit on non-motor symptoms (NMS). Methods: A retrospective multicenter cohort study was conducted, in which the clinical effect of safinamide on both motor and NMS was assessed by the Clinical Global Impression of Change scale. Furthermore, we assessed the appearance of adverse events (AEs) and its effect on dyskinesia, that were also recorded in non-fluctuating PD patients and in those previously treated with rasagiline. Results: We included 213 PD patients who received safinamide in addition to their regular levodopa therapy. Thirty-five withdrew prematurely from safinamide, mainly because of AEs. Out of 178, clinical improvement on motor and NMS was found in 76.4% and 26.2%, respectively. A total of 44 reported AEs of mild intensity. We did not find a difference concerning the clinical benefit or AEs when comparing either patients who had or had not been taking Monoamine Oxidase B Inhibitor (MAOB-I) previously or between patients with and without motor complications. Conclusions: Safinamide is an effective and safe add-on to levodopa drug for PD patients. Moreover, safinamide could elicit an additional clinical improvement in PD patients previously treated with other MAOB-I and in non- fluctuating patients with suboptimal motor control.
format Online
Article
Text
id pubmed-6826846
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-68268462019-11-18 Safinamide in Clinical Practice: A Spanish Multicenter Cohort Study Martí-Andrés, Gloria Jiménez-Bolaños, Rayco Arbelo-González, José Matias Pagonabarraga, Javier Duran-Herrera, Carmen Valenti-Azcarate, Rafael Luquin, Mª Rosario Brain Sci Article Background: Safinamide is an approved drug for the treatment of motor fluctuations of Parkinson’s Disease (PD) patients with a potential benefit on non-motor symptoms (NMS). Methods: A retrospective multicenter cohort study was conducted, in which the clinical effect of safinamide on both motor and NMS was assessed by the Clinical Global Impression of Change scale. Furthermore, we assessed the appearance of adverse events (AEs) and its effect on dyskinesia, that were also recorded in non-fluctuating PD patients and in those previously treated with rasagiline. Results: We included 213 PD patients who received safinamide in addition to their regular levodopa therapy. Thirty-five withdrew prematurely from safinamide, mainly because of AEs. Out of 178, clinical improvement on motor and NMS was found in 76.4% and 26.2%, respectively. A total of 44 reported AEs of mild intensity. We did not find a difference concerning the clinical benefit or AEs when comparing either patients who had or had not been taking Monoamine Oxidase B Inhibitor (MAOB-I) previously or between patients with and without motor complications. Conclusions: Safinamide is an effective and safe add-on to levodopa drug for PD patients. Moreover, safinamide could elicit an additional clinical improvement in PD patients previously treated with other MAOB-I and in non- fluctuating patients with suboptimal motor control. MDPI 2019-10-11 /pmc/articles/PMC6826846/ /pubmed/31614574 http://dx.doi.org/10.3390/brainsci9100272 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Martí-Andrés, Gloria
Jiménez-Bolaños, Rayco
Arbelo-González, José Matias
Pagonabarraga, Javier
Duran-Herrera, Carmen
Valenti-Azcarate, Rafael
Luquin, Mª Rosario
Safinamide in Clinical Practice: A Spanish Multicenter Cohort Study
title Safinamide in Clinical Practice: A Spanish Multicenter Cohort Study
title_full Safinamide in Clinical Practice: A Spanish Multicenter Cohort Study
title_fullStr Safinamide in Clinical Practice: A Spanish Multicenter Cohort Study
title_full_unstemmed Safinamide in Clinical Practice: A Spanish Multicenter Cohort Study
title_short Safinamide in Clinical Practice: A Spanish Multicenter Cohort Study
title_sort safinamide in clinical practice: a spanish multicenter cohort study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6826846/
https://www.ncbi.nlm.nih.gov/pubmed/31614574
http://dx.doi.org/10.3390/brainsci9100272
work_keys_str_mv AT martiandresgloria safinamideinclinicalpracticeaspanishmulticentercohortstudy
AT jimenezbolanosrayco safinamideinclinicalpracticeaspanishmulticentercohortstudy
AT arbelogonzalezjosematias safinamideinclinicalpracticeaspanishmulticentercohortstudy
AT pagonabarragajavier safinamideinclinicalpracticeaspanishmulticentercohortstudy
AT duranherreracarmen safinamideinclinicalpracticeaspanishmulticentercohortstudy
AT valentiazcaraterafael safinamideinclinicalpracticeaspanishmulticentercohortstudy
AT luquinmarosario safinamideinclinicalpracticeaspanishmulticentercohortstudy